SNM Annual Meeting Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     



J Nucl Med. 2008; 49 (Supplement 1):374P
This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Dimitrakopoulou-Strauss, A.
Right arrow Articles by Strauss, L.
PubMed
Right arrow Articles by Dimitrakopoulou-Strauss, A.
Right arrow Articles by Strauss, L.

Oncology-Clinical Diagnosis: Solid Tumors

Clinical Diagnosis-Solid Tumors Posters

Prediction of therapy outcome in patients with high risk soft tissue sarcomas (STS) using dynamic FDG follow-up studies

Antonia Dimitrakopoulou-Strauss1, Bernd Kasper2, Gerlinde Egerer2, Uwe Haberkorn1 and Ludwig Strauss1

1 Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany; 2 Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany

1581

Objectives: To evaluate the FDG metabolism in patients (pts.) with high risk STS receiving chemotherapy with regard to the prediction of therapy outcome.

Methods: The evaluation includes 27 pts. with high grade STS. 14 pts. received an induction chemotherapy with adriamycin and ifosfamide (AIG, 6 cycles) and 13 pts. a preoperative chemotherapy with etoposide, ifosfamide and doxorubicin (EIA, 4 cycles). Pts. were examined prior to therapy and after the 1st cycle of AIG or the 2nd cycle of EIA respectively. The restaging data of 27 pts. (14 pts. with AIG and 13 pts. with EIA) served for reference including CT and/or MRI.

Results: According to RECIST criteria, 3 pts. showed no evidence of disease (NED), 6 partial remissions (PR), 13 stable diseases (SD), and 5 pts. progressive disease (PD). We dichotomized the data in pts. with NED/PR (n = 9) and SD/PD (n = 18). Median SUV prior therapy was 4.7 SUV (5.2 SUV for NED/PR and 3.8 SUV for SD/PD) in comparison to 3.0 SUV (4.0 SUV for NED/PR and 2.93 SUV for SD/PD) after chemotherapy. Median influx was 0.037 prior to chemotherapy in comparison to 0.014 following therapy. The change of kinetic parameters after chemotherapy was not statistically significant between the response-groups and nor between the studies. We used discriminant analysis (DA) to classify the patients into the two response groups. DA revealed a correct classification rate of 88 % using all kinetic data (absolute values) of both studies and 79% using the difference of all kinetic data.

Conclusions: On the basis of these results, kinetic FDG data are helpful for the prediction of chemo-sensitivity in patients with high risk sarcomas.





This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Dimitrakopoulou-Strauss, A.
Right arrow Articles by Strauss, L.
PubMed
Right arrow Articles by Dimitrakopoulou-Strauss, A.
Right arrow Articles by Strauss, L.